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ABSTRACT
Background As screening methods for colorectal
cancer (CRC) are limited by uptake and adherence,
further options are sought. A blood test might increase
both, but none has yet been tested in a screening
setting.
Objective We prospectively assessed the accuracy of
circulating methylated SEPT9 DNA (mSEPT9) for
detecting CRC in a screening population.
Design Asymptomatic individuals ≥50 years old
scheduled for screening colonoscopy at 32 US and
German clinics voluntarily gave blood plasma samples
before colon preparation. Using a commercially available
assay, three independent blinded laboratories assayed
plasma DNA of all CRC cases and a stratified random
sample of other subjects in duplicate real time PCRs. The
primary outcomes measures were standardised for overall
sensitivity and specificity estimates.
Results 7941 men (45%) and women (55%), mean
age 60 years, enrolled. Results from 53 CRC cases and
from 1457 subjects without CRC yielded a standardised
sensitivity of 48.2% (95% CI 32.4% to 63.6%; crude
rate 50.9%); for CRC stages I–IV, values were 35.0%,
63.0%, 46.0% and 77.4%, respectively. Specificity was
91.5% (95% CI 89.7% to 93.1%; crude rate 91.4%).
Sensitivity for advanced adenomas was low (11.2%).
Conclusions Our study using the blood based mSEPT9
test showed that CRC signal in blood can be detected in
asymptomatic average risk individuals undergoing
screening. However, the utility of the test for population
screening for CRC will require improved sensitivity for
detection of early cancers and advanced adenomas.
Clinical Trial Registration Number: NCT00855348
INTRODUCTION
Colorectal cancer (CRC) afflicts 1 35 000 and kills
51 000 Americans every year, with similar rates in
most European countries.1 2 A blood test that detects
asymptomatic CRC could be clinically useful.
Aberrant methylation as a regulator of gene
expression has been demonstrated in tumours in
general3 and for CRC specifically.4 Aberrantly
methylated genes are attractive candidate markers
for cancer detection, as cancer specific methylation
occurs early in tumorigenesis, appears to be stable,
yields an amplifiable signal and can be assayed with
high accuracy.5 As methylation occurs in distinct
genomic areas, methylated markers in tumour
tissue6 and in body fluids7 are likely targets for also
detecting cancer in its early forms.
Methylated SEPT9 DNA (mSEPT9) was identi-
fied by comparing candidate markers in normal
colonic epithelium and CRC tissue samples
through methylation sensitive restriction enzyme
based marker discovery followed by microarray and
real time PCR.8 Over 90% of tumour tissue had
relative quantities of mSEPT9 above the highest
relative quantities found in normal colon mucosal
tissue. Previous independent case control studies
using clinically confirmed CRC cases and colonos-
copy verified healthy asymptomatic controls sug-
gested that detecting mSEPT9 in plasma may
indicate the presence of CRC.8–10 In these studies,
the overall sensitivity for CRC using DNA derived
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Significance of this study
What is already known on this subject?
▸ Screening for colorectal cancer (CRC) is
commonly done by stool tests and colonoscopy,
but uptake and adherence may limit benefit.
▸ A blood test alternative might improve uptake
and adherence to CRC screening.
▸ Plasma methylated SEPT9 DNA (mSEPT9) was
shown to be about 70% sensitive and 90%
specific for CRC detection in retrospective case
control studies.
What are the new findings?
▸ This is the first prospective study in a screening
population with bloods collected prior to colon
preparation. The analytic method was based on
analysis of plasma DNA in two PCR replicates,
as recommended by the manufacturer at the
time the study was performed. Sensitivity of
mSEPT9 for detection of CRC was 48.2%
sensitive; it was 91.5% specific.
How might it impact on clinical practice in
the foreseeable future?
▸ With improved performance characteristics to
detect early cancer and advanced adenomas,
the mSEPT9 assay could play a role in CRC
screening.
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from 3–5 ml plasma and a triplicate PCR reaction averaged
around 70%, with a false positive rate of approximately 10%.
We therefore prospectively assessed the performance of this
marker in a screening setting in a large asymptomatic population
undergoing screening colonoscopy.
PATIENTS AND METHODS
The PRospective Evaluation of SEPTin 9 (PRESEPT)11 was a mul-
ticentre US and German study, sponsored by Epigenomics AG, to
estimate the ability of mSEPT9 to detect invasive adenocarcinoma
of the colorectum in asymptomatic individuals, aged 50 years and
older, meeting average risk screening guidelines.12 This ability is
measured by the sensitivity; additionally, specificity and predictive
values of the assay are important to clinical utility. Secondary end-
points included sensitivity for advanced (clinically significant)
adenomas (AA) and for non-advanced (clinically insignificant)
adenomas (NA). Statistical design, data management and analysis
were performed by an independent statistical centre (Health
Studies Section, Division of Environmental Health Sciences,
University of Minnesota School of Public Health). Other than the
statistical centre, all study personnel were fully masked to subject
specific assay results. However, for identification of unforeseen
workflow errors, laboratory personnel were given assay result dis-
tributions, including frequency of positives, negatives and invalids
for comparison with historical values.
Ethics committees in Germany and institutional review
boards in the USA approved the study, and all subjects were
informed and signed a consent form. An independent Clinical
Studies Steering Committee (CSSC) made scientific decisions
regarding the study and oversaw operations. mSEPT9 assay
results were not disclosed to subjects or their physicians and
played no role in clinical care.
The PRESEPT Study, Evaluation of SEPT9 Biomarker
Performance for CRC Screening, is registered at ClinicalTrials.gov,
Trial Registration ID: NCT00855348.11 The protocol is accessible
at https://www.healthstudies.umn.edu/trc/presept/presept_protocol
_rev_2.pdf (accessed 5 Jul 2012).
Population
Subjects at least 50 years old and scheduled for colonoscopy at
one of the participating clinical centres were approached about
volunteering for the study. To ensure that only average risk indi-
viduals were enrolled, we excluded those with previous lower
endoscopy, previous CRC or adenomas; iron deficiency anaemia
or haematochezia (blood in the stool) within the previous
6 months; or family history indicating increased risk for the
disease (two or more first degree relatives with CRC or one or
more with CRC at age 50 years or less; or known Lynch syn-
drome or familial adenomatous polyposis). To increase accrual,
approximately 6 months after study initiation the CSSC revised
the initial eligibility criteria to no longer exclude subjects with
flexible sigmoidoscopy more than 5 years before enrolment.
Eligibility was assessed through authorised medical record
review or subject interview, according to the centre.
Clinical procedures
At least 1 day before initiating colonoscopy preparation,
enrolled eligible subjects provided informed consent for the
study, baseline information and a single whole blood draw into
four 10 ml potassium ethylenediaminetetraacetic acid blood
tubes. Plasma was isolated from whole blood,10 aliquoted into
coded 2 ml cryotubes and stored at −80°C. Aliquot batches
were periodically shipped on dry ice to a central repository for
−80°C storage.
Because the intent was to evaluate the assay in the context of
routine screening and the centres used were experienced at
screening, no attempt at study wide control of colonoscopy or
pathology procedures or quality was made. Rather, colonoscopy
procedures, including polypectomy and biopsy, were performed
by board certified endoscopists at each of the participating
centres using board specific screening standards and site specific
standards for sedation, monitoring, imaging and equipment.
This was to mimic actual screening to the extent possible.
Histopathology, diagnostic procedures, and staging of biopsy
and surgical specimens used routine procedures at each site.
Colonoscopy and pathology reports, including completion and
preparation quality, were abstracted onto study forms and
entered into the database.
Laboratory methods
Assay of samples from subjects with CRC and subjects without
CRC randomly selected from each pathology substratum were
in turn randomly allocated to one of three independent labora-
tories (ARUP, Salt Lake City, Utah, USA; Charite, Berlin,
Germany; Quest, San Juan Capistrano, California, USA). The
number of samples sent to each laboratory was governed by
expected throughput. These laboratories, blinded to the subject
clinical results, used the first generation commercially available
assay, the Epi proColon Assay (Epigenomics AG, Berlin,
Germany), comprised of a plasma DNA preparation kit, work-
flow control kit (containing the positive and negative controls)
and real time PCR kit, to perform all of the laboratory assays,
and were trained and qualified on the procedures described in
the protocol.
The Epi proColon Assay used in this study was previously
described by Rösch and Weiss.13 Briefly, free circulating DNA
from 3.5 ml of plasma, obtained through pooling of two ali-
quots of subject plasma each containing ∼2 ml, was captured on
magnetic beads, purified and concentrated. To ensure only
methylated cytosine was replicated, the unmethylated cytosine
in the purified DNA was then chemically converted to uracil
using sodium bisulfite. DNA was then captured again on mag-
netic beads, purified through washing steps and eluted in a final
volume of 55 μl. The resulting bisulfite converted DNA was
amplified in a duplex PCR comprised of oligonucleotides for an
internal control assay, actin β for determining the validity of the
result and oligonucleotides for the target analyte, methylated
Septin9. Two separate PCR replicates were prepared with the
bisulfite converted DNA eluate from each subject sample by
adding 15 ml of eluate to each of two wells of a 96 well PCR
plate. Prior to adding subject DNA to the PCR plate, 25 ml of a
mixture of PCR buffer, oligonucleotides and polymerase were
added to the entire 96 well plate. Real time PCR was performed
on an LC480 device (Roche Diagnostics, Indianapolis, Indiana,
USA). The remaining ∼25 ml of bisulfite converted DNA mater-
ial was frozen at −80°C and stored. Technical details, including
preparation of the master mix, oligonucleotide sequences and
concentrations, and the recommended cycling parameters, are
available in the supplementary assay information, which is avail-
able as an online supplement.
Positive and negative controls from the workflow control kit
were processed with each batch of samples. The positive work-
flow control contained genomic DNA derived from the HeLa
cell line, which is methylated in the region of septin 9 targeted
by the assay. The negative workflow control contains genomic
DNA derived from the Jurkat cell line in which the targeted
septin 9 region is not methylated. Results within runs where the
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workflow controls did not give expected results and individual
samples with inadequate DNAwere considered invalid.
PCR curves for mSEPT9 were generated. If a curve exceeded
the prespecified threshold within 50 PCR cycles, the reaction
was positive (see the online supplementary assay information
for exceptions). If at least one PCR replicate from a subject was
positive, the assay was positive. Theoretically, patients with early
onset of CRC could present with mSEPT9 DNA levels
approaching one genomic equivalent (∼2 copies) per plasma
sample. In order to detect this small amount of circulating
DNA, multiple PCR replicates are used to extend the limit of
detection of the assay beyond that of a single PCR reaction.
Electronic copies of the results using blind identifiers were
forwarded directly to the statistical centre. For samples with
invalid results on the initially retrieved samples, two additional
cryotubes were retrieved, processed and assayed for a second
and final attempt. Some cases with invalid results could not be
reassayed due to insufficient sample volume.
Classification of pathology
Based on review of the clinical and histopathological characteris-
tics documented on study data forms, the CSSC, prior to assay,
assigned each adequate colonoscopy outcome (those with
adequate preparation and complete to the caecum) to one of
four clinical classes: CRC, AA, NA or no evidence of disease
(NED). In addition, invasive CRC was subclassified into stages
I–IV14; AA were subclassified into high grade dysplasia (HGD),
villous architecture without HGD or large polyps (≥10 mm)
with neither HGD nor villous architecture.
As the accuracy of the mSEPT9 marker for detection of CRC
was the primary objective of this study, to identify potential mis-
classification of invasive CRC as HGD, or vice versa, histo-
pathological diagnoses for all T1 CRC and all HGD and
carcinoma in situ diagnoses (which were grouped as HGD if
confirmed on reanalysis) from each site’s local pathologist were
independently reviewed by two study pathologists (an independ-
ent CSSC member and a sponsor study team member) using ori-
ginal diagnostic slides or their images. In the case of
disagreement with the original diagnosis, the agreement of two
out of three pathologists prevailed.
Post hoc study of a third PCR reaction
In order to analyse the effect of a different and possibly
improved analysis method, a single post hoc study examined the
impact of an additional PCR replicate (ie, three rather than two
wells per subject) on sensitivity and specificity. Because the assay
target is available in small quantities, particularly for some early
stage cancers, the assay clearly has a stochastic component to it
and hence a particular PCR reaction may lack adequate
numbers of mSEPT9 copies to trigger DNA amplification. By
providing another opportunity to generate a positive result,
adding a third PCR measurement necessarily increases sensitivity
and decreases specificity, but the amount of change depends on
the degree of dependence between the individual PCR results
for an individual. To estimate this change, we emulated this
three PCR replicate assay by performing an additional blinded
PCR reaction on the main study subjects with available residual
∼25 μl of the original bisulfite converted DNA, producing a
third PCR curve assessed for positivity by the same criterion as
for the first two PCR reactions. A subject was positive if any of
the three PCR replicates were positive (either of the two original
PCR replicates or the third post hoc replicate). As this post hoc
study was done in response to initial results from the main
study indicating lower than expected sensitivity of the original
assay, it is an exploratory analysis and, unlike the main study
result, cannot be considered a validation.
Statistical design and analysis
Enrolment of 7500 subjects was intended to produce 50 CRC.
Subjects with incomplete colonoscopies or diagnosed with
non-CRC were excluded from the analyses. The target popula-
tion comprised US and German residents at least 50 years old,
based on the 2000 US Census Bureau Database15 and 2000 US
Census Bureau International Database.16 Both countries have
opportunistic CRC screening programmes that include screening
colonoscopy without national invitation or incentive systems.
During accrual, successive batches of enrolled subjects
meeting analysability criteria (ie, adequate colonoscopy, com-
plete diagnosis, sufficient blood sample) were sampled for
laboratory analysis. The planned distribution for the selected
samples was 50 CRC, 300 AA, 200 NA and 900 NED (1450
total). This was based on the primary objective, to estimate sen-
sitivity, specificity and predictive values for CRC and secondary
objectives to estimate sensitivity for AA and for NA, and to
accrue as many HGD as possible. The sample size of 50 CRC
was selected to yield a 95% CI for sensitivity of width of no
more than 0.29; the number of AA was to produce a CI no
wider than 0.12; the number of NA was to yield a CI no wider
than 0.14; and the total number of non-CRC (the sum of AA,
NA and NED) was to provide a CI no wider than 0.07. All pre-
viously unselected CRC and HGD available at the time of batch
sample selection and randomly selected subsets of the other
diagnostic groups were included in each batch for laboratory
analysis. The diagnostic groups were allocated to laboratories
proportionately. The blind identifiers of selected subjects were
provided to the study sponsor, who managed the shipment of
plasma samples to the participating laboratories. As the labora-
tories processed each batch, they reported mSEPT9 assay results
to the statistical centre.
Crude estimates of the probability of a positive assay
(‘positivity’) for different subgroups were obtained by simple
ratios. Because sampling was not proportional at any level (eg, age
groups were sampled with differing proportions, cases without
CRC or HGD were under sampled), estimators were standardised
to the target population using the direct method17 18 and inverse
probability weighting.19 The direct method applies the positivity
rates seen in the study population to the structure of the target
population. Standardising and weighting covariates were age, sex,
ethnicity, enrolment date and diagnostic group. Age and sex fre-
quencies for the USA and Germany were used. Specificity was esti-
mated as 1−positivity among subjects without CRC. Estimates of
positive (PPV) and negative (NPV) predictive values were based on
the sampling scheme described above. The standard non-
parametric bootstrap20 was used to produce 95% CI. For extreme
binomial outcomes (eg, 5/5), ‘exact’ confidence limits were used.21
Estimates of differences in proportions among subgroups were
similarly standardised. V.2.10.1 of the R statistical software system
was used for all computations.22 Details of the sampling of subjects
for analysis and the data analysis techniques are contained in the
Statistical Analysis Plan, available as online supplementary assay
information.
RESULTS
Subjects were enrolled from June 2008 until January 2010.
Thirty-two clinical sites—22 in the USA and 10 in Germany—
participated, enrolling 7941 subjects. Six subjects were diag-
nosed with cancers other than CRC: one case each of anal squa-
mous cell carcinoma, ovarian carcinoma with positive lymph
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nodes and invasion into the colon, cloacogenic/basaloid type
squamous cell carcinoma of the rectum and hepatocellular car-
cinoma; and two rectal carcinoids.
The modified STAndards for the Reporting of Diagnostic
accuracy studies (STARD) diagram in figure 1 gives the dispos-
ition of all subjects enrolled in the study.23 Nine withdrew but
their baseline data were used in the calculation of weights; 12
German subjects withdrew and their data were redacted in
accordance with German law. The time between sample collec-
tion and colonoscopy averaged 14 days (IQR 6–16 days).
Samples from 6874 subjects were available for selection into
laboratory analysis, including 53 CRC and 3025 adenomas; this
represents an adenoma detection rate of 44.8%. Six laboratory
batches were generated by the method described above. Among
the 53 cancer cases, 66% were men and mean age was 67 years;
among the non-CRC subjects, 45% were men and mean age
was 61 years. Figure 2 gives the age–sex distribution for the
study sample and the target population from the USA and
Germany combined. The biggest difference was a higher pro-
portion of younger individuals compared with the oldest age
categories in the study sample compared with the target popula-
tion structure.
Assay accuracy measures
Figure 3 plots the standardised positivity rates and CI for the
mSEPT9 assay results by diagnostic outcome of the
Figure 1 Enhanced STAndards for the Reporting of Diagnostic accuracy studies (STARD) diagram of the disposition of subjects in the study,23
based on the template at http://www.stard-statement.org. aGerman law requires that data from subjects in Germany who withdrew cannot be
retained or used for study purposes. bCR, colorectal. cSample either had too little volume or was unusable. dHGD, high grade dysplasia. eCases
selected for laboratory analysis in a stratified random sampling.
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colonoscopy. Sensitivity and specificity (1−positivity among
‘non-CRC’ subjects) were 48.2% (95 % CI 32.4% to 63.6%)
and 91.5% (95% CI 89.7% to 93.1%), respectively. PPV and
NPV were 5.2% (95% CI 3.5% to 7.5%) and 99.5% (95% CI
99.2% to 99.6%), respectively.
With respect to different tumour stages, stage specific sensitiv-
ity was 35.0% for stage I, 63.0% for stage II, 46.0% for
stage III and 77.4% for stage IV; combined sensitivities for
stages I–II versus III–IV were 44.7% vs 54.9%; combined sensi-
tivity for stages I–III (those with any chance of improvement in
survival) was 45.1%. For AA, sensitivity was 11.2%, only min-
imally higher than the positivity rate for subjects without any
pathology (9.1%).
Age and sex
As shown in figure 4, the assay showed greater sensitivity and
specificity in younger subjects (<65 years of age) than in older
ones, but the differences were not statistically significant. The
assay had higher sensitivity in women than in men but specifi-
city was equivalent; again, these differences were not statistically
significant.
Distal versus proximal disease
Sensitivities for distal and proximal CRC were 53.3% (95% CI
34.7% to 72.4%) versus 39.4% (95% CI 14.2% to 68.2%),
respectively (p=0.282). Note that these analyses did not
address different distributions between subgroups by either
stage of cancer or polyp subtypes.
Individual PCR results
Among those 53 subjects with CRC, there were 26 (49.1%)
who had neither replicate positive, eight (15.1%) who had only
one and 19 (35.8%) who had both. The comparable numbers
among those 1463 subjects without CRC were 1331 (91.0%),
110 (7.5%) and 16 (1.1%), respectively, with the remaining six
(0.4%) invalid.
Post hoc three replicate emulation
Adequate bisulfite converted DNA for a third PCR replicate was
available for 51 (of 53) CRC and 1427 (of 1457) non-CRC
cases of those previously analysed. Standardised sensitivity and
specificity values of the three replicate assay were 63.9% (95%
CI 47.5% to 79.2%) and 88.4% (95% CI 86.2% to 90.4%),
respectively. PPV and NPV were 4.82% (95% CI 3.53% to
6.73%) and 99.63% (95% CI 99.38% to 99.79%), respectively.
For AA, sensitivity was 14.4%, slightly higher than the positivity
rate for subjects with no pathology (12.1%).
DISCUSSION
In this prospective study using colonoscopy as the reference
standard, we assessed the ability of a plasma based DNA
marker, mSEPT9, to detect preclinical CRC in blood samples
collected prospectively from an average risk screening popula-
tion. Retrospective case control studies had suggested that
detectable levels of mSEPT9 in plasma identify individuals with
CRC with a sensitivity between 52% and 72% and specificity
between 90% and 95%.8–10 Another recent case control study
by Warren et al24 obtained estimates of 90% for the sensitivity
and 88% for the specificity of mSEPT9. These previous study
Figure 2 PRospective Evaluation of SEPT (PRESEPT) results: target population and study subjects, age–sex distribution. Target sample and study
sample distributions compared by sex and 5 year intervals of age at enrolment from 50 to 80 years (50–54, 55–59, etc). For the PRESEPT study
sample (n=1516), the lowest interval of age (50, 55 years) includes one subject aged <50 years. Similarly, the highest interval (75, 80 years)
includes 23 subjects who were aged 80 years or more. Proportions extending to the right in each plot represent proportions of the PRESEPT study
sample overall; the sum of all proportions from both plots is 1. Proportions extending to the left in each plot represent proportions of the German
and US population in the year 2000.
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results motivated the present prospective study, which was per-
formed in a screening setting, in contrast with previously pub-
lished results derived from cases diagnosed symptomatically
(thus likely to be qualitatively different from asymptomatic
cases) and convenience sample controls (which may not repre-
sent the asymptomatic population) and so had limited generalis-
ability.25 Our study design and analysis avoided those pitfalls;
our results demonstrated lower sensitivity than the previous case
control studies.
The primary assay used for the study, based on the first com-
mercially available mSEPT9 assay, could detect 48.2% of cases
of preclinical CRC with 91.5% specificity in the target popula-
tion. Most of the CRC identified during the course of examin-
ation were stages I–III, and sensitivity was lower for earlier
tumour stages. Sensitivity was very low for AA and only slightly
higher than the false positive rate for all individuals who did
not have cancer, indicating that there is at present no utility in
detecting important precancerous lesions.
Screening for CRC not only reduces mortality from the
disease26–29 but also incidence.30 31 However, a national survey
in the USA reported that only about 50% of the eligible popula-
tion had been screened according to guidelines.32 In Germany, a
survey among 1808 randomly selected persons revealed that
about 40% of those over the age of 50 years had undergone
some form of colonoscopy.33 Blood based tests have long been
sought in the cancer detection field for their convenience and
potential for higher compliance; nevertheless, higher uptake,
higher yield of precancerous lesions and finally any effect on
mortality would still have to be shown. At present, it can there-
fore only be speculated whether a blood test with faecal occult
blood test (FOBT)-like performance would produce similar
reductions in incidence and mortality to those seen in previous
randomised FOBT trials.26–29 Our study only assessed perform-
ance in a screening setting, and cannot assess other factors such
as uptake. In comparison with FOBT, which is still widely used
and implemented in some national programmes,34 the mSEPT9
assay yielded a CRC sensitivity of 48%, which is at the lower
end of the guaiac FOBT range (37–79%).35 The specificity of
mSEPT9 was 92%, compared with a range of 87–98% for the
guaiac test.35 PPV for standard rehydrated guaiac FOBT used in
the Minnesota study was 5.6%,26 compared with 5.2% for
mSEPT9 in this study. However, these comparative performance
characteristics would suggest that, even in a programme of
repetitive annual screening, use of the mSEPT9 assay would not
produce a decline in mortality commensurate to that seen with
a sensitive guaiac test.
Furthermore, newer faecal immunochemical stool tests for
haemoglobin (FIT) may provide improved performance charac-
teristics36 as well as slightly superior uptake rates37; therefore,
FIT is increasingly being used instead of guaiac FOBT in
Figure 3 Methylated SEPT9 (mSEPT9) positivity rates by clinical findings. mSEPT9 assay positivity estimates and 95% CI by outcome category,
standardised to the target population. Dot represents point estimate (Est), bars represent 95% CI. AA, advanced adenomas; CRC, colorectal cancer;
HGD, high grade dysplasia; NA, non-advanced adenomas; NED, no evidence of disease; Test, raw result of assay; P, number of positive assays; Tot,
number of valid measurements.
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countries introducing screening programmes (eg, The
Netherlands).38 A newer faecal DNA test has reported sensitiv-
ities of 85% for CRC and 54% for adenomas ≥1 cm (based on
a single case control design using a stool bank).39 The same
group40 recently evaluated mSEPT9 in parallel with a stool
based DNA test in a small retrospective study in CRC and large
adenomas. The study also reported a modest sensitivity and very
low AA detection rate for mSEPT9. They estimated the sensitiv-
ity of mSEPT9 for large adenomas at 14% and for CRC 60%,
somewhat higher than our study, but with larger CI. The source
of the samples was the Mayo Tumour Registry, but the exact
selection criteria for the samples are not given and the mSEPT9
test was not performed in the same manner. In the same study,
comparative sensitivity of faecal DNA was higher for cancer
(87%) as well as adenomas ≥1 cm (82%). However, evidence
from these latter studies is limited as they were neither per-
formed prospectively nor in a screening setting.
As a large proportion of human CRC tissue contains relatively
high amounts of mSEPT9 regardless of tumour stage, improve-
ment of DNA isolation or increased PCR efficiency may result
in better marker performance. Unfortunately, tissue samples
from the current study were not collected for testing to deter-
mine whether the tumours contained significant amounts of
mSEPT9. Improvements in the test appear to be possible, as
shown by our post hoc analysis using the three PCR replicate
emulation which mimics the second generation commercially
available mSEPT9 assay and which detected nearly two-thirds of
cases, but yielded false positives in 12% of non-cases. The three
replicate approach needs to be tested prospectively. The emula-
tion used in this post hoc analysis imprecisely reproduced a sim-
ultaneous three replicate assay, for three reasons: (1) the
decision to look at a third PCR replicate was based on lower
than expected two replicate assay sensitivity, leading to lower
estimated three replicate assay sensitivity; (2) the third PCR
replicates were not done in the same run on the same machine
as the first two, unlike an actual three PCR replicate assay,
allowing increased run to run variation to lower the assay dis-
crimination; and (3) criteria for invalid results differ slightly
because in practice, all three replicates would have common
control samples and be subject to the same probability of inval-
idity. For these reasons, estimated sensitivity of the three repli-
cate assay is likely to be smaller than true sensitivity; the effect
on specificity is less clear but probably small. Thus the three rep-
licate results are strictly exploratory. In addition, because the
assay is working with what are small quantities, the assay clearly
involves a stochastic component, and hence a particular PCR
replicate may lack adequate numbers of mSEPT9 copies to
trigger DNA amplification. Additional replicates merely provide
more opportunities to yield a positive, thus increasing sensitivity
while decreasing specificity. Therefore, it can only be speculated
whether this more recent assay version might perform better in
the screening setting. Similarly, we do not know whether the
accuracy of the three replicate mSEPT9 assay might approximate
available immunochemical stool tests. Still, detection of aden-
omas as precursor lesions would also have to be improved. The
choice of a blood based assay, such as mSEPT9, in a programme
Figure 4 Methylated SEPT9 (mSEPT9) assay positivity estimates by age, sex and clinical findings. Comparing mSEPT9 assay positivity estimates
and 95% CI by age group and outcome category and by sex and outcome category, standardised to the target population. Dot represents point
estimate (Est), bars represent 95% CI. AA, advanced adenomas; CRC, colorectal cancer; HGD, high grade dysplasia; NA, non-advanced adenomas;
NED, no evidence of disease; Test, raw results of assay; P, number of positive assays; Tot, number of valid measurements.
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of CRC screening depends on multiple features not assessed in
this study, including the potential for increased compliance, the
necessary frequency of testing and features of competing tests,
such as cost. The current cost of the mSEPT9 test in Europe is
approximately 150 Euros, considerably more than faecal tests
but less than a colonoscopy. In any event, the comparative
effectiveness and cost of various strategies of screening with
mSEPT9 requires further evaluation.41 42
There are limitations to our study:
▸ Because the centres enrolling in the study were not ran-
domly sampled and study subjects were sampled from the
study centres disproportionately by clinical findings for
laboratory testing, standardisation to some target screening
population was necessary to obtain relevant performance
estimates. Although in any non-random sample there may
be unknown factors for which standardisation is impos-
sible and there is always some error in the standardisation
variables, our standardisation included the main determi-
nants of CRC incidence, age and sex, and they had negli-
gible measurement errors.
▸ To increase accrual, the entry criterion regarding prior
endoscopy was relaxed soon after the beginning of enrol-
ment. This probably reduced the overall prevalence rate,
but we believe it had little impact on the assay parameter
estimation.
▸ Although no split sample quality control was performed to
examine consistency between laboratories, there was no
statistically significant difference in the frequency of find-
ings between them (data not shown).
▸ Although subjects with other cancers found on examin-
ation were excluded from the primary analysis, sensitivity
analyses including these cases only slightly affected the
quantitative results (analyses not shown).
It should also be mentioned that we do not believe that the
mSEPT9 results are generalisable to other blood based tests for
CRC. To the contrary, each marker should be evaluated not only
in isolation but also as an adjunct to other markers, much as
Ahlquist and colleagues43 have done with stool based markers.
In conclusion, the blood based mSEPT9 assay detected about
half of the preclinical CRC with specificity similar to guaiac
based FOBT, in this prospective masked study of screening sub-
jects. Sensitivity of mSEPT9 for advanced adenomas was very
low. Although this renders the clinical utility very low, there
might be ways to achieve possible improvements, as suggested
by our post hoc analysis as well as by a recent case control
study.24 The utility of the test for population screening for CRC
will require improved sensitivity for detection of early cancers
and advanced adenomas. Nevertheless, these and all other tests
potentially to be used for CRC screening have to be prospect-
ively tested in the screening setting, where they would finally be
applied. One implication of our study is that performance esti-
mates may differ substantially in such settings compared with
retrospective case control studies.
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